Literature DB >> 15371634

Cardiovascular outcomes of pediatric seroreverters perinatally exposed to HAART: design of a longitudinal clinical study.

Jill E Lavigne1, William T Shearer, Bruce Thompson, E John Orav, Thomas J Starc, Steven D Colan, Ricardo Pignatelli, Sharon E O'Brien, Louis Bezold, Phillip LaRusa, Kirk A Easley, Irene Cheng, Sarah A Duffy, Steven E Lipshultz.   

Abstract

Seroreverters (uninfected children of HIV-infected mothers) have exhibited left ventricular (LV) dysfunction. Mitochondrial toxicity associated with in utero or postnatal exposure to highly active antiretroviral therapy (HAART) is a possible mechanism. Adult and animal models have demonstrated associations between LV abnormalities, cardiomyopathy, and components of HAART. Yet, outcomes in children are poorly understood. In this study, we explore HAART-associated LV abnormalities in seroreverters exposed to HAART (n = 144) or never exposed (n = 252). Subjects are drawn from the Women and Infants Transmission Study and the Pediatric Pulmonary and Cardiovascular Complications of HIV Study, respectively. Data include (1) echocardiographic studies of LV structure and function and (2) serologic cardiac biomarkers (cardiac troponin, probrain natriuretic peptide, high-sensitivity C reactive protein), both collected during the first month of life, and again at 6, 12, 24, 36, and 48 months postnatally. Planned analyses include several regression models. At this time, we have access to data for all 252 unexposed children, and 53 exposed subjects are enrolled. The cohorts are similar in terms of gender and race and the recruited subjects are representative of all eligible subjects in terms of exposure to HAART. Recruitment will continue into 2006.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15371634     DOI: 10.1385/ct:4:2:187

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN: 1530-7905            Impact factor:   3.231


  3 in total

1.  Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study).

Authors:  Steven E Lipshultz; William T Shearer; Bruce Thompson; Kenneth C Rich; Irene Cheng; E John Orav; Sulekha Kumar; Ricardo H Pignatelli; Louis I Bezold; Philip LaRussa; Thomas J Starc; Julie S Glickstein; Sharon O'Brien; Ellen R Cooper; James D Wilkinson; Tracie L Miller; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2011-01-04       Impact factor: 24.094

2.  Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers.

Authors:  Steven E Lipshultz; Paige L Williams; Bret Zeldow; James D Wilkinson; Kenneth C Rich; Russell B van Dyke; George R Seage; Laurie B Dooley; Jonathan R Kaltman; George K Siberry; Lynne M Mofenson; William T Shearer; Steven D Colan
Journal:  AIDS       Date:  2015-01-02       Impact factor: 4.177

3.  Cardiac Effects of Highly Active Antiretroviral Therapy in Perinatally HIV-Infected Children: The CHAART-2 Study.

Authors:  Steven E Lipshultz; James D Wilkinson; Bruce Thompson; Irene Cheng; David A Briston; William T Shearer; E John Orav; Joslyn A Westphal; Tracie L Miller; Steven D Colan
Journal:  J Am Coll Cardiol       Date:  2017-10-31       Impact factor: 24.094

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.